Ferring Pharmaceuticals acquiring Gameto for up to $1.38bn
Swiss pharmaceutical group Ferring Pharmaceuticals has entered into a definitive agreement to acquire New York-based biotechnology company Gameto in a transaction valued at up to $1.38bn. The acquisition represents a major strategic expansion for Ferring in its core therapeutic area of reproductive medicine and maternal health. The transaction features a structured payment system that includes an upfront payment alongside substantial…
ARCHIMED takes majority stake in medical imaging cloud company
Global healthcare private equity specialist ARCHIMED has announced that its Healthcare IT team has acquired a majority stake in 3verest, a London-headquartered provider of sovereign cloud infrastructure dedicated to medical imaging. For healthcare operators and investors, the transaction highlights the rising critical importance of data sovereignty in clinical environments. Unlike traditional cloud providers that often resell capacity from global hyperscalers,…
EQT acquires molecular diagnostics specialist in €10.80bn takeover
Swedish private equity group EQT is acquiring listed German-Dutch diagnostics specialist Qiagen in a transaction that values the target at an enterprise value of approximately €10.80bn. The transaction represents a major consolidation in the European life sciences and molecular diagnostics landscape. Qiagen operates extensively across sample preparation, molecular diagnostics, and life sciences research fields, with its technologies widely deployed in…
Merck to acquire London biotech company for $1.1bn
German multinational science and technology company Merck KGaA has announced a definitive agreement to acquire London-headquartered biotech company Silence Therapeutics. This transaction represents a significant expansion of the Darmstadt based group’s rare disease and specialty healthcare portfolio, reinforcing its ambition to become a global leader in specialised innovation. The deal carries an enterprise value of roughly $1.1bn. The transaction’s primary…
AstraZeneca agrees $1.5bn AI Deal and $2bn partnership
Biopharmaceutical giant AstraZeneca has struck two significant deals: a strategic drug discovery collaboration and licensing agreement with US-based artificial intelligence therapeutics specialist Insitro, and a two billion dollar strategic transaction with US, UK and Ireland-based oncology specialist Summit Therapeutics. Under the terms of the Insitro agreement, AstraZeneca will pay Insitro an upfront payment of $40m. Insitro is also eligible to…
US REIT to acquire 45 UK care homes for £1.1bn
US listed CareTrust REIT has announced a £1.1bn agreement to acquire a portfolio of 45 purpose built care homes from LNT Care Developments, marking a significant expansion of its United Kingdom footprint. This is a transformative step for the California-based real estate investment trust as it seeks to build a substantial senior housing operating portfolio platform across the British market.…
Voyage Care acquires Orchard Healthcare Group
Voyage Care has successfully completed the acquisition of Orchard Healthcare Group, marking a major consolidation in the UK specialist care sector. The deal involves the 100 per cent acquisition of Orchard by Voyage Care, a leading provider of specialist support backed by the investment firm Wren House Infrastructure. This strategic move is particularly significant for investors as it expands Voyage…
Ribera acquires Valencian hospital group HCB
Spanish healthcare delivery operator Ribera, a subsidiary of French private hospital group Vivalto Santé, has acquired Valencian private hospital group HCB Hospitales. Operating for over 40 years, the acquired group manages a healthcare network comprising two acute hospitals located in Benidorm and Dénia, three outpatient clinics in Calpe, Moraira, and Albir, and two diagnostic imaging centers in Alicante, supported by…
GE HealthCare acquires $945m Sofie Biosciences
Global MedTech and diagnostocs leader GE HealthCare has acquired Sofie Biosciences, a privately-held developer of radiopharmaceuticals and molecular imaging diagnostics, in a transaction valued at $945 million. The deal marks a major step forward in GE HealthCare’s strategy to expand its precision diagnostics business and secure greater operational control over the highly complex and time-sensitive radiopharmaceutical supply chain. Molecular imaging…
H. Lundbeck divests Italian pharma manufacturing subsidiary
Listed Danish pharmaceutical giant H. Lundbeck is divesting its Italian manufacturing subsidiary, Lundbeck Pharmaceuticals Italy, to Flamma, a privately owned Italian contract development and manufacturing organisation (CDMO). While the exact financial terms and transaction value have not been publicly disclosed, the deal marks a significant strategic realignment for both organisations. For Lundbeck, the divestment represents a deliberate effort to streamline…